New triple diabetes pill tested in healthy adults
NCT ID NCT07399470
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study looks at how a new pill that combines three diabetes medicines (gemigliptin, dapagliflozin, and metformin) works in healthy adults. About 58 people will take either the new combination pill or the three drugs separately, then switch. The goal is to see if the combination pill works the same way in the body. This is a Phase 1 trial, so it focuses on safety and how the drug is processed, not on treating a disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FASTING CONDITIONS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jeonbuk National University Hospital
Jeonju, Jeollabuk-do, 54907, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults